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SUMMARY
This study aimed to define the number and type of complications associated with the
Wada test at an academicmedical center for comparison to previous reports.We per-
formed a retrospective review of medical records for patients who underwent the
Wada test at the University of Michigan between April 1991 and June 2013. Informa-
tion was collected regarding the angiography procedure and the immediate postoper-
ative period to assess for both clinical and angiographic complications. A total of 436
patients were identified who underwent theWada procedure between April 1991 and
June 2013, and 431 patients were included in the final analysis. Twenty-five patients
(5.8%) had notable clinical events associated with the Wada test. Nine patients (2.1%)
had clinical events meeting criteria for complication, which included seizures, status
epilepticus, internal carotid artery vasospasm, inadvertent injection of anesthetic in
the external carotid artery, and transient encephalopathy. No complications were
associated with significant morbidity or mortality. This retrospective review of
patients undergoing the Wada test found significantly fewer associated complications
in comparison to previously published studies, with no patients experiencing long-
termmorbidity. TheWada test should be considered a safe diagnostic tool for lateral-
izing language andmemory.
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The Wada test, or intracarotid amobarbital procedure
(IAP), is often used to determine language and memory lat-
eralization in candidates for epilepsy surgery, and has been
referred to as the “gold standard” for this purpose. However,
with the development of noninvasive functional neuroimag-
ing methods, including functional magnetic resonance
imaging (fMRI), magnetoencephalography (MEG), and
transcranial magnetic stimulation (TMS) to lateralize
language function, the continued use of the Wada test has
been questioned.1–3 One reason is that the Wada test is inva-
sive, as it requires the insertion of a catheter into the internal
carotid artery (ICA). The complication rates associated with
cerebral angiography and Wada testing range from 0.3% up
to nearly 11% of patients undergoing the procedure, with
the Wada test reported near the upper end of this range.4–7
With this knowledge, it makes sense to question the contin-
ued use of a decades old invasive test as the primary modal-
ity for lateralizing language and memory. However, in
contrast to previous reports citing complications in nearly
11% of patients, our experience has been that the Wada test
is a relatively safe procedure. We report our experience at
an academic medical center for comparison to previous
reports, to accurately define the risks associated with the
Wada test.
Methods
Institutional review board approval was granted prior to
beginning the study (study ID# HUM00057420). A data-
base of patients who underwent theWada test between April
1991 and June 2013 at the University of Michigan was used
to perform a retrospective chart review. Data were collected
on the occurrence of any significant clinical event (e.g., sei-
zures, groin hematomas, unanticipated change in neurologic
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condition, and failure to complete testing due to an unex-
pected clinical event) that occurred at the time of Wada test-
ing, during the peri-angiography period, or within 1 month
of the procedure. A procedure complication was defined as
an unintended adverse and undesirable development in a
patient that was clinically significant, requiring medical
treatment, additional resource use, or prolonged hospitaliza-
tion. Any unanticipated change in neurologic condition
during or immediately after the procedure was deemed to be
procedure related. Neurologic changes related to the
patient’s underlying illness (e.g., seizures in patients with
known intractable epilepsy) were not considered procedure-
related complications. Arteriotomy-related hematomas
were considered complications if they required consultative
evaluation, treatment, or prolonged hospitalization. Patients
undergoing procedures immediately following Wada test-
ing (e.g., embolization) were excluded due to an inability to
distinguish complications associated with the procedure
from complications associated with the Wada test. Calcula-
tion of percent complications was performed using Micro-
soft Excel.
All Wada tests were performed by first gaining arterial
access with micropuncture and Seldinger technique, using
either 5- or 4-French sheaths. Catheterization of the ICA
was then performed and a road map was created by conven-
tional angiography. Anesthetic was then given by hand-push
injection. Amobarbital was used exclusively as the anes-
thetic of choice until May 1998, at which point either
methohexital or amobarbital was used. Amobarbital was no
longer used after July 2004, with methohexital being used
exclusively through June 2013. Dosing used for amobarbital
was typically a single injection of 100–125 mg into each
ICA. Dosing used for methohexital was typically 5–7 mg
into each internal carotid artery, divided into two doses.
Additional procedure details can be found in previously
published reports on the use of amobarbital and methohex-
ital for theWada test.8,9
Results
Of 436 patients who underwent the Wada test between
April 1991 and June 2013 at the University of Michigan, a
total of 431 patients were included for review. Four patients
were excluded due to lack of documentation in the elec-
tronic medical record, and one patient was excluded because
he had an embolization procedure for an arteriovenous mal-
formation immediately following the Wada test. Of 431
patients, a total of 25 (5.8%) experienced an unintended
clinical event during or immediately after the Wada test,
although only 9 (2.1%) of those patients had clinical events
meeting our criteria that were considered complications. A
summary of all unintended clinical events, as well as those
events meeting criteria to be considered complications, can
be found in Table 1, with details of each of the complica-
tions found in Table 2.
Among the patients who had arteriotomy-related hemato-
mas, none met criteria considered to be complications, as
none required additional resource use or deviation from the
usual postoperative observation and care. Of the six patients
who had seizures around the time of theWada test, two were
considered to be complications, as they occurred during the
procedure and resulted in repeating Wada testing at a later
date due to the patients being in a postictal state. Of note,
one patient had a seizure prior to injection of anesthetic but
after angiography, which suggests that the seizure was coin-
cident with the test, as opposed to causally related. All three
patients with encephalopathy had transient alteration of
consciousness after the first injection of anesthetic, which
precluded completion of Wada testing, requiring repeated
testing at a later date. One patient had right ICA vasospasm
with luminal filling defects and reported numbness and tin-
gling in the left finger tips during the procedure, which
resolved by completion of the procedure. This event was
concerning for a transient ischemic attack (TIA). This
patient had theWada test completed at a later date. A second
patient had ICA vasospasm on the left side, followed by
complete resolution of vasospasm after verapamil infusion
during the same procedure. This event was considered a
complication due to requirement for medical treatment. One
patient had anesthetic inadvertently injected into the exter-
nal carotid artery twice during the same test, with conflict-
ing neuropsychological testing results after eventual
successful injection of both ICAs, prompting repeated
Wada testing at a later date due to concern for an encepha-
lopathy confounding the results. Finally, one patient was
hospitalized for 2 days for status epilepticus, with the
presumed cause due to delayed administration of the
patient’s scheduled antiepileptic doses during the day of
Wada testing. No long-term morbidity was associated with
this complication.
Discussion
The percentage of patients who had a complication
during the Wada test between April 1991 and June 2013
Table 1. Procedure-related clinical events and
complications duringWada testing among 431 reviewed
cases
Clinical event
Number of
patients (%)
Number of patients
meeting criteria for
complication (%)
Arteriotomy-related hematoma 13 (3.0) 0 (0)
Encephalopathy 3 (0.7) 3 (0.7)
Injection of external carotid artery 1 (0.2) 1 (0.2)
Internal carotid artery vasospasm 2 (0.5) 2 (0.5)
Seizure 6 (1.4) 2 (0.5)
Status epilepticus 1 (0.2) 1 (0.2)
Total 25 (5.8)a 9 (2.1)
aOne patient had both an arteriotomy-related hematoma and a seizure.
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at the University of Michigan was 2.1%. One pooled
multicenter, combined study of patients who underwent
Wada testing between 2000 and 2005 reported that
1.09% of patients had a complication,4 which is similar
to our result, as well as that reported for general cere-
bral angiography (0.3–1.3%).5,6 In contrast, a single-cen-
ter study from 2008 by Loddenkemper et al. reported
complications in up to 10.9% of cases, which is cited
frequently in recent literature discussing the relative
safety of the Wada test for language lateralization.7,10
These discordant data may reflect a distinction between
reporting unintended, insignificant clinical events associ-
ated with the Wada test versus significant complications.
Understanding these risks is important, as the Wada test
clearly remains useful in patients without clear language lat-
eralization or with suspected atypical language lateraliza-
tion.10 When contemplating the risks and benefits of
performing the Wada test, an additional factor to consider is
the variability among medical centers and clinicians with
regard to experience and expertise, and the impact this may
have on complication rates. Despite recent advances, a
similar argument should also be made for noninvasive
functional tests, as the ability of functional magnetic reso-
nance imaging (fMRI) to predict postsurgical memory out-
comes has yet to be reliable or validated across centers and
requires additional investigation.11,12 Although the reliabil-
ity of the Wada test for lateralizing memory has been dis-
puted, it can predict postsurgical memory impairment, and
thus remains clinically important in some patients with epi-
lepsy.13 Therefore, the Wada test should remain an impor-
tant diagnostic option for patients with epilepsy who are
candidates for epilepsy surgery.
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Table 2. Clinical details of nine patients who experienced unintended clinical events, whichmet criteria to be
considered complications
Complication Clinical details
Criteria met to be
considered complication Date ofWada test
Age
(years) Gender Anesthetic
Encephalopathy Wada repeated due to inability to perform
testing during second injection
Additional resource use November 12, 1991 41 Female Amobarbital
Encephalopathy Wada repeated due to inability to perform
testing during second injection
Additional resource use November 17, 1993 37 Male Amobarbital
Encephalopathy Wada repeated due to inability to perform
testing during second injection
Additional resource use February 1, 1999 44 Female Amobarbital
Anesthetic injection
into ECA
Inconsistent responses duringWada test,
possible encephalopathy
Additional resource use December 7, 1992 23 Female Amobarbital
Wada later repeated to validate results
Seizure Seizure after angiography was completed,
before anesthetic injection
Additional resource use July 9, 1991 10 Male Amobarbital
Wada later repeated due to
postictal state
Seizure Seizure after first anesthetic injection Clinically significant
neurologic change
and additional
resource use
November 17, 1992 34 Male Amobarbital
Wada later completed due
to postictal state
Status epilepticus Missed medication dose
during day of testing
resulting in status
epilepticus and 2-day hospitalization for
treatment and observation
Clinically significant
neurologic change and
additional resource use
May 3, 2010 9 Male Methohexital
ICA vasospasm Resolved following infusion of verapamil Medical treatment March 21, 2007 21 Female Methohexital
No transient or permanent
neurologic changes
ICA vasospasm TIA (clinically significant
neurologic change,
with subsequent resolution)
Clinically significant
neurologic change,
medical treatment,
and additional
resource use
May 17, 2006 46 Male Methohexital
Wada later completed after resolution
of vasospasm
ECA, external carotid artery; ICA, internal carotid artery; TIA, transient ischemic attack.
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